Pegfilgrastim successfully mobilizes megakaryocyte progenitors into the peripheral blood in subjects with solid tumours

Bone Marrow Transplantation

Volumn 42, Issue 3, 2008, Pages 167-173

  Willis, F ^a   Theti, D ^a   Dean, S ^a   Bacon, P ^b   Baker, N ^c   Pettengell, R ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b AMGEN INC   (United States)

^c AMGEN LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CD41A ANTIGEN; LYMPHOCYTE ANTIGEN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MULTICENTER STUDY; OVARY CANCER; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOLID TUMOR; STEM CELL MOBILIZATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CARBOPLATIN; COLONY-FORMING UNITS ASSAY; COMBINED MODALITY THERAPY; FILGRASTIM; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MEGAKARYOCYTES; MIDDLE AGED; NEOPLASMS; PACLITAXEL; STEM CELLS;

EID: 50149104547     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.147     Document Type: Article

References (47)

1. Nademanee A, Molina A, Dagis A, Snyder DS, O'Donnell MR, Parker P et al. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma. Clin Lymphoma 2000; 1: 46-54.
2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
3. Fermand JP, Ravaud P, Chevret S, Divine, M, Leblond V, Belanger C et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-3136.
4. Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003; 349: 7-16.
5. Ledermann JA, Herd R, Maraninchi D, Viens P, Buclon M, Philip T et al. High-dose chemotherapy for ovarian carcinoma? long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2001; 12: 693-699.
6. Cohena Y, Nagler A. Hematopoietic stem-cell transplantation using umbilical-cord blood. Leuk Lymphoma 2003; 44: 1287-1299.
7. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
8. Vicent MG, Madero L, Chamorro L, Madero R, Diaz MA. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies. Haematologica 2001; 86: 1087-1094.
9. Dawson MA, Schwarer AP, Muirhead JL, Bailey MJ, Bollard GM, Spencer A. Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who have failed a previous attempt with a granulocyte colony-stimulating factor-based regimen. Bone Marrow Transplant 2005; 36: 389-396.
10. Faucher C, Le Corroller AG, Chabannon C, Viens P, Stoppa AM, Bouabdallah R et al. Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: The number of CD34 + cells reinfused is the only factor predicting both granulocyte and platelet recovery. J Hematother 1996; 5: 663-670.
11. Filshie RJ. Cytokines in haemopoietic progenitor mobilisation for peripheral blood stem cell transplantation. Curr Pharm Des 1002; 8: 379-394.
12. Linker C, Anderlini P, Herzig R, Christiansen N, Somlo G, Bensinger W et al. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. Biol Blood Marrow Transplant 2003; 9: 405-413.
13. Sohn SK, Kim JG, Seo KW, Chae YS, Jung JT, Suh JS et al. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2002; 30: 81-86.
14. Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB et al. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple mycloma. Biol Blood Marrow Transplant 2004; 10: 395-404.
15. Somlo G, Sniecinski I, ter Veer A, Longmate J, Knutson G, Vuk-Pavlovic S et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood 1999; 93: 2798-2806.
16. Diaz MA, Vicent MG, Garcia-Sanchez F, Vicario JL, Madero L. Long-term hematopoietic engraftment after autologous peripheral blood progenitor cell transplantation in pediatric patients: Effect of the CD34+ cell dose. Vox Sang 2000; 79: 145-150.
17. Feng R, Shimazaki C, Inaba T, Takahashi R, Hirai H, Kikuta T et al. CD34+/CD41a+ cells best predict platelet recovery after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1998; 21: 1217-1222.
18. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991; 78: 2791-2808.
19. Chao NJ, Schriber JR, Grimes K, Lung GD, Negrin RS, Raimondi CM et al. Granulocyte, colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993: 81: 2031-1035.
20. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell ttansplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
21. Lickliter JD, Begley CG, Boyd AW, Szer J, Grigg AP. Combined chemotherapy and granulocyte colony-stimulating factor (G-CSF) mobilise large numbers of peripheral blood progenitor cells in pretreated patients. Leuk Lymphoma 1994; 15: 91-97
22. Horvath N, Hahn U, Joshua D, Dyson P, Gibson J, Stevens J et al. Long-term follow up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: A multimodality approach. Intern Med J 2004; 34: 167 175.
23. Stewart DA, Guo D, Luider J, Auer I, Klassen J, Morris D et al. The CD34+90+ cell dose does not predict early engraftment of autologous blood stem cells as well as the total CD34 + cell dose. Bone Marrow Transplant 2000; 25: 435-440.
24. Diaz MA, Vicent MG, Garcia-Sanchez F, Vicario JL, Madero L. Long-term hematopoietic engraftment after autologous peripheral blood progenitor cell transplantation in pediatric patients: Effect of the CD34+ cell dose. Vox Sang 2000; 79: 145-150.
25. Ayala IA, Tomer A, Kellar KL. Flow cytornetric analysis of megakaryocyte-associated antigens on CD34 cells and their progeny in liquid culture. Stem Cells 1996; 14: 320-329.
26. Hogge DE, Lambie K, Sutherland HJ, Bermy W13. Dalal B. Currie C et al. Quantitation of primitive and lineage-committed progenitors in mobilized peripheral blood for prediction of platelet recovery post autologous transplant. Bone Marrow Transplant 2000; 25: 589-598.
27. Curran MP, Goa KL. Pegfilgrastim. Drugs 2002; 62: 1207-1213.
28. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27: 1724-1734.
29. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim, in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
30. Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-fisk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727-731.
31. Johnston E, Crawford J, Blackwell S, Bjurstrorn T, Lockbaum P, Roskos L et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18: 2522-2528.
32. Isidori A, Tani M, Bonifazi F, Zinzani P, Curti A, Motta MR et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphorna, patients. Haematologica 2005; 90: 225-231.
33. Demirer T, Buckner CD, Gooley T, Appelbaum FR, Rowley S, Chauncey T et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 937-941.
34. Morris CL, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A et al. Mobilization of CD34 + cells in elderly patients (>/=70 years) with multiple myeloma: Influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003; 120: 413-423.
35. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
36. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
37. Laricchia-Robbio L, Moscato S, Genua A, Liberati AM, Revoltella RP. Naturally occurring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum. J Cell Physiol 1997; 173: 219-226.
38. Welte K. Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): The first 10 years. Blood 1996; 88: 1907-1929.
39. Chakrabarti S. Takahashi Y. Read EJ. Khuu H. Goodwin R. Lettman S et al. A Comparison of apheresis cell content collected from the same donors mobilized with granulocyte colony stimulating factor (G-CSF) vs a single injection of AMD3 100. ASH Annual Meeting Abstracts 2004; 104: 2853.
40. Dugan MJ, Akard LP, Thompson JM, Nademanee A, Maziarz RT, Bensinger WI et al. Treatment with AMD3100 in multiple myeloma or non-Hodgkin's lymphoma patients to increase the number of peripheral blood stem cells when given with a mobilizing regimen of chemotherapy and G-CSF. ASH Annual Meeting Abstracts 2004: 104: 2860.
41. D'Hondt V, Humblet Y, Guillaume T, Baatout S. Chatelain C, Berliere M et al. Thrombopoietic effects and toxicity of interieukin-6 in patients with ovarian cancer before and after chemotherapy: A multicentric placebo-controlled randomized phase 1b Study. Blood 1995; 85: 2347-2353.
42. Gordon MS, Nemunaitis J, Hoffman R, Paquette RL, Rosenfeld C, Manfreda S et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995; 85: 3066-3076.
43. Tepler I, Elias L, Smith JW, Hussein M, Rosen G, Chang AY et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87: 3607-3614.
44. Molineux G, Hartley C, McElroy P, McCrea C, McNiece IK. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients. Blood 1996; 88: 366-376.
45. Wolff SN, Herzig R, Lynch J, Ericson SG, Greer JP, Stein R et al. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: A phase I pharmacokinetic and pharmacodynamic study. Bone Marrow Transplant 2001; 27: 261-268.
46. Basser RL, O'Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002; 99: 2599-2602.
47. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241-3248.